ZEISS Medical Technology will showcase digital enhancements and surgical solutions at the AAO conference from Oct. 19-21, in Chicago. These solutions across cataract, corneal refractive, retina and glaucoma workflows, offer new, enhanced paths to patient management and treatment, using a digitally connected environment to help advance the clinical workflow to support a higher level of personalized care, the company said in a press release. 
 
Extending the ZEISS digital portfolio, the company will introduce ZEISS VisioGen, an AI-driven solution designed to enhance refractive patient communication and streamline clinic operations. According to the company, ZEISS VisioGen leverages generative AI (GenAI) for patient acquisition-as-a-service. The software solution provides digital communication services to offer fast, high-quality responses to patients. ZEISS VisioGen enables clinics to respond more effectively to patient inquiries while converting more patients to consultations using the latest GenAI technology combined with substantiated and verified content from ZEISS to generate personalized draft responses to patient queries for clinical staff to finalize and use, the company said in the press release. 
 
In addition, the company will also showcase the recently FDA-approved VISUMAX 800 with SMILE pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The updated ZEISS femtosecond laser provides US refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements as compared to the previous generation VisuMax, the company said. The VISUMAX 800 creates the lenticule in less than 10 seconds by using a higher laser pulse repetition rate of 2 MHz. According to the company, the ZEISS femtosecond laser also provides a smaller footprint and compatibility with a variety of patient beds, adapting to the clinical environment.
 
In addition, ZEISS will demonstrate the ZEISS MICOR 700, which was recently FDA cleared and is now broadly available in the United States. According to the company, the ZEISS MICOR 700 is the first hand-held lens removal device with ultrasound-free operation. Designed to create a gentler patient experience, the ZEISS MICOR 700 offers a patented crystalline lens extraction technology, a blunt and rounded tip design and a single-use “plug & play” system with a minimal operating room footprint.
 
ZEISS will also showcase its expanded portfolio of high-end microscopes with the ZEISS ARTEVO 850 3D heads-up ophthalmic microscope with true color imaging, and increased depth of field by nearly 60%, the company said. Additionally, the ZEISS ARTEVO 850 with CALLISTO eye features a redesigned intuitive user interface that centralizes all controls on a single touchscreen. The second latest addition to ZEISS’s portfolio of optical surgical microscopes, the new ARTEVO 750, introduces advanced optical visualization technology, including new RGB LED illumination with adjustable light color temperature, as well as data overlays provided in the eyepiece with a 40% increase in resolution. The two devices are CE-marked and FDA cleared and commercially available in all major markets.
 
At AAO, ZEISS will also showcase its comprehensive portfolio across the entire ZEISS Retina Workflow, now combining diagnostic solutions with advanced visualization and vitreoretinal surgical systems and next generation therapeutic lasers. The ZEISS Retina Workflow offers connected and integrated solutions that help eye-care professionals to deliver optimized patient care from early detection, through monitoring, to in-office or surgical treatments.
 
ZEISS will also showcase imaging technology and 3D visualization as part of the ZEISS Retina Workflow. The CIRRUS 6000 from ZEISS introduces an expanded Reference Database, triple that of its previous database, with greater diversity and three different disc sizes for more individualized patient care, the company said. With an acquisition speed of 100,000 A scans per second, the device provides instantaneous dense data cubes and sub-10-second-wide-field OCT Angiography capability, together with automated 9 slab standard report presentation to complement the review process. In addition, the ZEISS ARTEVO 850 includes customizable digital color settings depending on the surgical procedure’s needs and intraoperative OCT allowing for real-time monitoring of the surgical process and decision-making.
 
The newest addition to the ZEISS Retina Workflow, the DORC EVA NEXUS surgical system and instrumentation bring added value and synergy to the OR, the company said. The DORC vitreoretinal portfolio includes the EVA NEXUS phacovitrectomy system featuring the VTi pump, offering FLOW and VACUUM fluidics, EVA AVETA trocar cannula system with Push-Fit HI-FLOW infusion connection, two-dimensional cutting vitrectomy with cut speeds of up to 20,000 CPM, EVA INICIO microinjection system, and a range of posterior instruments including 27G ULTRA for small-gauge surgery, as well as a wide range of highly purified posterior surgical liquids and tamponades.
 
Finally, ZEISS' next generation therapeutic laser portfolio received 510k FDA clearance for two models, the VISULAS combi, which combines YAG and 532 modalities, and the standalone VISULAS green (532) laser. One of the key benefits of the ZEISS VISULAS portfolio is the digital connection to the FORUM data management solution, allowing surgeons to seamlessly integrate laser therapy into the ZEISS Retina Workflow, ensuring a high level of efficiency throughout the entire process, the company said. 
 
ZEISS will showcase its latest offerings and new innovations at the AAO conference from Oct. 19-21, in Chicago at booth 4816.